Get started
Author

Kevin Ye Hou

Observed names: Hou, Kevin, Kevin Hou, Kevin Y Hou
OpenAlex ID: A5005977824
Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis.
2013 · Hans-Michael Kvasnicka, Juergen Thiele, et al. · Journal of Clinical Oncology · 30
Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
2018 · Moshe Talpaz, Susan Erickson-Viitanen, et al. · Journal of Hematology & Oncology · 25
PDF
Neurofilament light (NfL) chain levels predict clinical decline in Alzheimer's disease: A systematic review and meta-analysis
2025 · Kim Thomas, Paul Spin, et al. · Journal of Alzheimer s Disease Reports · 11
Three steps toward dose optimization for oncology dose finding
2024 · Jason J.Z. Liao, Ekaterine Asatiani, et al. · Contemporary Clinical Trials Communications · 9
Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309
2022 · Annie Im, Daniel Wolff, et al. · Blood · 8
Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis
2018 · Srdan Verstovsek, Swamy Yeleswaram, et al. · Hematological Oncology · 8
PDF
A hybrid design for dose‐finding oncology clinical trials
2022 · Jason J. Z. Liao, Feng Zhou, et al. · International Journal of Cancer · 6
PDF
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma
2026 · Shaji Kumar, Sundar Jagannath, et al. · Blood Cancer Journal · 4
PDF
The Effect of Health Care Disparities on Complications and Mortality in Sickle Cell Disease
2018 · Stuthi Pavani Perimbeti, Kevin Ye Hou, et al. · Blood · 4
Autologous Stem Cell Transplant: A Cost Effective and Efficacious Treatment for Newly Diagnosed Multiple Myeloma
2016 · Seema Niphadkar, Indumathy Varadarajan, et al. · Blood · 4
A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis
2025 · Moshe Talpaz, Aaron T. Gerds, et al. · Leukemia Research · 3
Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis
2024 · Shaji Kumar, Sundar Jagannath, et al. · Blood · 3
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States
2026 · Shaji Kumar, Katja C. Weisel, et al. · Blood Cancer Journal · 1
PDF
MSR88 Key Considerations in the Use of Large Language Models for Data Extraction in Health Economics and Outcomes Research
2025 · Elise Aronitz, Jayson Brian Habib, et al. · Value in Health · 1
Opioid Dependency Significantly Increases Complications and Mortality in Sickle Cell Disease
2018 · Stuthi Pavani Perimbeti, Kevin Ye Hou, et al. · Blood · 1
Itacitinib plus calcineurin inhibitor–based therapy for prophylaxis of graft-versus-host disease: GRAVITAS-119 results
2026 · Nirav N. Shah, Hannah Choe, et al. · Bone Marrow Transplantation
PDF
MSR53 Development and Validation of an LLM-Based Study Selection Tool for Automating Systematic Literature Reviews: Achieving Time Efficiency and Maintaining Gold Standard Accuracy
2025 · Christopher Olsen, Jayson Brian Habib, et al. · Value in Health
Issues in cox proportional hazards model with unequal randomization
2024 · Hongfei Li, Qian H. Li, et al. · Journal of Biopharmaceutical Statistics
Three steps towards dose optimization for oncology dose finding
2023 · Liao, Jason J. Z., Asatiani, Ekaterine, et al. · arXiv (Cornell University)
PDF
Adherence to the guidelines: A comparison of biomarker testing implementation in metastatic non-squamous, non-small cell lung cancer in university versus community institutions.
2019 · Sufana Shikdar, Zachary Michael Trisel, et al. · Journal of Clinical Oncology
Adverse Outcomes in Concurrent Sickle Cell Disease and Hematological Malignancies
2018 · Stuthi Pavani Perimbeti, Kevin Ye Hou, et al. · Blood
Prevalence and mortality of colorectal cancer with iron deficiency anemia in the South.
2017 · Stuthi Perimbeti, Kevin Ye Hou, et al. · Journal of Clinical Oncology
Racial differences of iron deficiency anemia in gastric cancer.
2017 · Stuthi Perimbeti, Erika Correa, et al. · Journal of Clinical Oncology
Works count: 23
Citation count: 117
H-index: 6
I10-index: 3
Year
Topic
Type